1, Beijing Institute of Biological Products
Beijing Institute of Biological Products (Beijing Institute) is the earliest unit engaged in microbiology, immunology research and production of epidemic prevention products in China. At present, there are 1473 employees and 6 12 scientific and technical personnel, accounting for 42% of the total employees. Among them, there are 88 senior technicians and 0/70 intermediate technicians. On August 5th, 2020, COVID-19 Inactivated Vaccine Workshop of Beijing Institute of Biological Products passed the joint biosafety inspection organized by relevant state departments and became the first inactivated vaccine workshop in COVID-19.
2 Beijing Kexing Zhongwei Biotechnology Co., Ltd.
On February 6th, 20021,the State Administration of Pharmaceutical Products approved the novel coronavirus inactivated vaccine Kelaifu developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. (hereinafter referred to as "Kexing Zhongwei") to be listed in China conditionally.
Extended data
Domestic vaccine production:
As of June 5438+February, 2020, there are five kinds of vaccines undergoing phase III clinical trials in China, namely inactivated vaccines of Zhongsheng Wuhan and Zhongsheng Beijing by China Pharmaceutical Group Co., Ltd., inactivated vaccine of Beijing Kexing Zhongwei Biotechnology Co., Ltd., adenovirus vector vaccine jointly developed by Academy of Military Sciences and Kangxinuo Company, and COVID-19 recombinant protein vaccine jointly developed by Institute of Microbiology of Chinese Academy of Sciences and Anhui Zhifeilong coma.
China News Network-COVID-19 vaccine mass production, China is ready.
China National Supervision and Administration Commission (NSC)—— China's first single-dose COVID-19 vaccine went on the market.